pulmonari
complic
common
often
lethal
hematopoiet
sct
recipi
object
prospect
intervent
studi
evalu
etiolog
diagnost
procedur
risk
factor
outcom
pulmonari
complic
cohort
hematopoiet
sct
recipi
follow
year
patient
suffer
pulmonari
complic
diagnost
algorithm
includ
noninvas
bronchoscop
procedur
perform
identifi
pulmonari
complic
patient
pneumonia
noninfecti
complic
undiagnos
virus
particularli
rhinoviru
bacteria
particularli
p
aeruginosa
respect
common
caus
pneumonia
specif
diagnosi
obtain
case
noninvas
test
gave
specif
diagnosi
episod
diagnost
yield
bronchoscopi
pulmonari
infect
earli
bronchoscopi
day
higher
diagnost
yield
late
bronchoscopi
vs
p
pulmonari
infect
overal
mortal
fatal
due
pulmonari
complic
pulmonari
complic
common
constitut
independ
risk
factor
mortal
stress
import
appropri
clinic
manag
pulmonari
complic
pc
among
common
lethal
complic
suffer
hematopoiet
sct
hsct
patient
increas
number
indic
select
debilit
patient
potenti
candid
hsct
seem
chang
epidemiolog
pc
studi
shown
immunocompromis
patient
earli
identif
etiolog
pc
improv
surviv
fiberopt
bronchoscopi
fob
import
role
diagnosi
pc
howev
detractor
techniqu
consid
inform
provid
may
also
obtain
differ
noninvas
explor
major
studi
evalu
etiolog
diagnosi
prognosi
pc
patient
hematolog
diseas
retrospect
includ
nontransplant
transplant
recipi
hypothes
prospect
followup
cohort
hsct
recipi
may
improv
clinic
manag
pc
first
knowledg
epidemiolog
pc
differ
preval
infecti
noninfecti
etiolog
accur
determin
second
predetermin
criteria
perform
fob
clarifi
role
techniqu
better
defin
diagnost
yield
clinic
implic
potenti
complic
final
identif
prognost
factor
much
precis
data
record
prospect
homogen
group
immunocompromis
patient
aim
studi
evalu
incid
diagnost
clinic
implic
noninvas
fob
explor
risk
factor
outcom
pc
aim
cohort
consecut
patient
requir
hsct
followedup
year
pc
close
analyz
prospect
intervent
studi
evalu
pc
cohort
consecut
hsct
recipi
followedup
year
figur
see
supplementari
inform
differ
variabl
record
inclus
studi
whenev
new
respiratori
complic
identifi
see
supplementari
inform
basi
result
diagnost
test
figur
clinic
judgment
physician
charg
empir
treatment
initi
decis
whether
patient
requir
hospit
admiss
diagnost
explor
made
comput
tomographi
request
h
detect
posit
aspergillu
galactomannan
antigen
day
persist
fever
despit
empir
treatment
prior
fob
whenev
explor
indic
fob
indic
respons
h
empir
treatment
figur
defin
earli
fob
procedur
perform
day
sinc
identif
pc
late
fob
perform
time
period
patient
elig
fob
arteri
mm
hg
oxygen
administr
bronchoscop
procedur
includ
bronchial
aspir
diffus
aspir
airway
secret
bronchoalveolar
lavag
bal
involv
instil
subsequ
aspir
ml
steril
salin
solut
two
aliquot
ml
involv
lobe
middl
lobe
lingula
patient
diffus
pulmonari
infiltr
diagnost
techniqu
transbronchi
biopsi
except
carri
select
patient
specif
primer
influenza
virus
type
b
c
respiratori
syncyti
viru
type
b
parainfluenza
virus
adenoviru
one
realtimepcr
assay
perform
bal
nasopharyng
swab
describ
previous
gener
detect
rhinovirus
enterovirus
anoth
realtimepcr
assay
detail
describ
supplementari
inform
cmv
detect
serum
done
use
monoclon
antibodi
protein
monofluo
kit
cmv
biorad
redmond
wa
usa
cultur
pcr
bal
detect
aspergillu
galactomannan
antigen
serum
bal
perform
use
enzym
immunoassay
method
platelia
aspergillu
sanofi
diagnost
pasteur
franc
etiolog
pc
establish
base
result
diagnost
procedur
perform
respons
specif
treatment
histopatholog
evalu
biopsi
sampl
avail
pc
divid
infecti
noninfecti
undetermin
pneumonia
defin
presenc
fever
cough
dyspnea
andor
purul
expector
new
progress
pulmonari
infiltr
explain
noninfecti
caus
diagnosi
viral
pneumonia
confirm
multiplex
revers
transcript
nest
realtimepcr
assay
perform
bal
mix
pneumonia
base
identif
pathogen
classif
proven
probabl
possibl
aspergillosi
establish
base
definit
consensu
european
organ
research
treatment
cancerinvas
fungal
infect
cooper
group
pulmonari
edema
diagnos
use
clinic
echocardiograph
criteria
cryptogenet
organ
pneumonia
druginduc
pulmonari
toxic
diagnos
histopatholog
sampl
obtain
transbronchi
openlung
biopsi
engraft
syndrom
defin
use
spitzer
criteria
capillari
leak
syndrom
defin
unexplain
weight
gain
within
h
gener
edema
nonrespons
furosemid
respons
empir
treatment
chest
xray
comput
tomographyscan
reveal
new
progress
lung
infiltr
andor
persist
fever
chang
therapi
addit
delet
treatment
attribut
posit
neg
result
bronchoscopi
among
patient
present
multipl
complic
episod
record
consid
independ
earlyl
pc
consid
appear
month
transplant
condit
regimen
immunosuppress
support
therapi
administ
follow
intern
accept
protocol
nonmyeloabl
regimen
use
patient
older
year
relev
comorbid
previou
transplant
allohsct
recipi
receiv
doubledrug
immunosuppress
gvhd
prophylaxi
donor
recipi
test
cmv
serolog
pretransplant
antiinfect
prophylaxi
levofloxacin
prescrib
engraft
fluconazol
also
preemptiv
strategi
cmv
infect
follow
accord
guidelin
hepafilt
room
alway
use
admiss
use
n
categor
variabl
mean
sd
continu
variabl
median
interquartil
rang
nonnorm
distribut
compar
categor
variabl
fisher
exact
test
unpair
student
ttest
use
compar
quantit
continu
variabl
group
nonnorm
distribut
analyz
use
mannwhitney
utest
univari
multivari
logist
regress
analys
perform
investig
clinic
factor
associ
increas
risk
mortal
variabl
show
signific
result
univari
includ
multivari
logist
regress
backward
stepwis
model
variabl
highli
correl
exclud
multivari
analys
hosmerlemeshow
goodnessoffit
test
perform
assess
overal
fit
model
surviv
curv
obtain
use
kalplanmei
method
compar
use
logrank
test
level
signific
set
two
tail
statist
analys
done
spss
version
spss
inc
chicago
il
usa
tabl
total
episod
pc
identifi
patient
studi
popul
patient
present
complic
patient
complic
patient
complic
patient
complic
specif
diagnosi
obtain
episod
evalu
total
episod
pneumonia
tabl
identifi
pc
frequent
viral
lung
infect
follow
bacteri
fungal
mix
infect
bacteri
viral
diagnos
five
episod
rhinoviru
respiratori
syncyti
viru
frequent
virus
isol
p
aeruginosa
frequent
involv
bacteria
caus
pneumonia
particular
p
aeruginosa
involv
diagnos
pulmonari
infect
consid
isol
mix
infect
thirtysix
percent
isol
p
aeruginosa
strain
multiresist
infect
occur
first
month
hsct
seventeen
patient
suffer
pulmonari
infect
neutropen
diagnosi
bacteri
infect
viral
infect
mix
infect
noninfecti
pc
tabl
identifi
episod
pulmonari
edema
underli
diseas
progress
common
etiolog
transbronchi
biopsi
perform
three
patient
persist
pulmonari
infiltr
empir
treatment
suspect
noninfecti
pc
remark
side
effect
transbronchi
biopsi
also
one
openlung
biopsi
requir
diagnos
case
pharmacolog
pulmonari
toxic
eightyon
percent
noninfecti
pulmonari
episod
earli
complic
pc
diagnos
first
month
infecti
noninfecti
appear
first
day
transplant
diagnost
yield
noninvas
diagnost
techniqu
sixteen
noninfecti
pulmonari
episod
diagnos
noninvas
techniqu
hand
noninvas
test
gave
specif
diagnost
episod
pneumonia
infecti
pc
specif
blood
cultur
posit
although
viral
pneumonia
identifi
cohort
diagnos
bal
interestingli
also
concord
posit
nasopharyng
swab
diagnost
yield
nasopharyng
swab
four
case
pneumonia
diagnos
urinari
antigen
test
one
case
also
confirm
blood
cultur
bronchial
aspir
bal
one
also
posit
blood
cultur
comput
tomographi
perform
episod
case
comput
tomographi
perform
time
symptom
appear
common
radiolog
find
patient
bacteri
pneumonia
consolid
viral
pneumonia
groundglass
opac
diagnost
yield
bronchoscop
techniqu
fob
perform
episod
earli
late
fob
reason
perform
delay
fob
initi
contraind
due
sever
respiratori
five
patient
progress
pulmonari
infiltr
four
patient
assess
pulmonari
infiltr
final
diagnos
noninfecti
pc
four
patient
overal
diagnost
yield
fob
percentag
increas
patient
infecti
pc
specif
diagnosi
obtain
fob
viral
pneumonia
patient
bacteri
pneumonia
patient
fungal
pneumonia
patient
mix
pneumonia
patient
diagnost
yield
differ
endoscop
techniqu
influenc
result
obtain
treatment
decis
shown
tabl
diagnost
yield
fob
pulmonari
infect
significantli
higher
perform
earli
earli
fob
vs
late
fob
p
differ
earli
late
fob
evidenc
regard
chang
empir
treatment
vs
p
ns
remark
side
effect
fob
figur
illustr
diagnost
yield
noninvas
test
fob
pulmonari
infect
abbrevi
adv
adenoviru
rsv
respiratori
syncyti
viru
relationship
type
transplant
risk
pc
particularli
evid
infecti
pc
consid
thu
pulmonari
infect
occur
allohsct
patient
autohsct
recipi
po
durat
neutropenia
vs
day
p
also
risk
factor
associ
pulmonari
infect
tabl
thirtytwo
percent
caus
mortal
due
pc
case
lethal
pc
due
infect
case
remark
p
aeruginosa
commonli
involv
microorgan
caus
death
lethal
pulmonari
infect
six
case
bacteri
pneumonia
die
compar
case
viral
pneumonia
p
allohsct
presenc
pc
grade
iiiv
acut
gvhd
durat
neutropenia
risk
factor
associ
overal
mortal
univari
analysi
tabl
multivari
analysi
allotransplant
presenc
pc
independ
risk
factor
mortal
tabl
model
predict
mortal
well
calibr
pvalu
hosmerlemeshow
test
present
studi
demonstr
pc
common
hsct
involv
almost
recipi
particularli
preval
first
month
transplant
pc
mostli
infecti
associ
mortal
rel
frequenc
differ
pc
vari
differ
posttransplant
period
sens
potenti
strength
present
studi
follow
patient
includ
cohort
year
accur
determin
preval
differ
pc
made
remark
virus
common
caus
pulmonari
infect
repres
pneumonia
note
episod
viral
pneumonia
mix
bacteria
virus
confirm
coinfect
common
occurr
patient
associ
mortal
viral
pneumonia
howev
import
role
virus
genesi
pc
reinforc
import
prevent
strategi
prospect
studi
bacteria
involv
identifi
pulmonari
infect
cohort
remark
p
aeruginosa
infect
repres
total
bacteri
infect
find
confirm
current
predomin
gramneg
rod
gramposit
cocci
observ
author
interestingli
fluoroquinolon
resist
frequent
p
aeruginosa
isol
probabl
owe
widespread
use
fluoroquinolon
prophylaxi
particularli
import
associ
mortal
p
aeruginosa
seri
therefor
implement
prophylact
protocol
period
reevalu
hsct
recipi
depend
differ
resist
pattern
institut
probabl
aspergillosi
diagnos
four
patient
account
diagnos
pulmonari
infect
low
incid
aspergillosi
like
result
intens
surveil
prophylact
program
design
avoid
infect
diagnost
evalu
pc
present
studi
confirm
major
pc
etiolog
identifi
signific
proport
episod
diagnos
implement
differ
noninvas
test
thu
avoid
requir
invas
procedur
remark
nasopharyng
swab
use
diagnost
tool
provid
diagnosi
viral
pneumonia
case
result
confirm
bal
azoulay
et
al
confirm
util
noninvas
test
critic
ill
hematolog
oncolog
patient
acut
respiratori
failur
controversi
role
fob
manag
pc
cohort
preestablish
criteria
perform
fob
overal
diagnost
yield
increas
pulmonari
infect
overal
episod
pulmonari
infect
could
diagnos
techniqu
almost
half
case
inform
obtain
caus
chang
empir
treatment
interestingli
case
neg
noninvas
test
diagnost
yield
fob
figur
demonstr
util
particular
scenario
even
patient
posit
noninvas
test
unsolv
unfavor
clinic
cours
fob
identifi
unsuspect
microorgan
case
figur
earli
fob
proport
signific
increas
isol
pathogen
compar
late
fob
mortal
former
group
somewhat
lower
although
differ
statist
signific
group
alreadi
shown
one
critic
factor
influenc
yield
fob
time
elaps
initi
symptom
fob
perform
establish
earli
diagnosi
lead
chang
empir
treatment
probabl
improv
prognosi
shannon
et
al
highlight
import
earli
diagnosi
demonstr
diagnost
yield
fob
wane
elaps
time
follow
clinic
present
seri
observ
remark
side
effect
fob
sens
conclus
demonstr
azoulay
et
al
prospect
random
studi
show
fob
increas
proport
patient
requir
mechan
ventil
reinforc
safeti
procedur
help
reluct
physician
care
patient
implement
procedur
earli
stage
although
prospect
inform
regard
outcom
hsct
recipi
scarc
overal
mortal
seri
fit
obtain
recent
aguilarguisado
et
al
allohsct
recipi
report
seri
relaps
diseas
chronic
gvhd
import
caus
mortal
interestingli
suffer
pc
particularli
one
infecti
origin
respons
onethird
overal
mortal
also
independ
risk
factor
mortal
stress
import
proper
clinic
manag
complic
limit
present
studi
patient
treat
singl
centr
sampl
size
rel
small
particularli
evalu
prognost
factor
howev
studi
includ
everi
hsct
perform
consecut
centr
followup
data
relat
complic
clinic
manag
obtain
prospect
summari
pc
hsct
recipi
common
seri
viral
infect
frequent
etiolog
howev
mortal
due
bacteri
pneumonia
particular
p
aeruginosa
much
higher
pc
respons
onethird
fatal
although
prospect
studi
shown
util
noninvas
test
potenti
role
fob
evolut
unfavor
must
confirm
control
trial
